Review
Nature Reviews Drug Discovery 7, 399-410 (May 2008) | doi:10.1038/nrd2550
Article series: Case Histories
Case history: Aliskiren: the first renin inhibitor for clinical treatment
Chris Jensen1, Peter Herold1 & Hans Rudolf Brunner1 About the authors
Abstract
The first evidence of the existence of renin was presented over 100 years ago. However, the importance of renin and the renin–angiotensin system in the pathogenesis of cardiovascular disease was only fully realized in the 1970s. It was another 20 years before the first inhibitors of renin were available for clinical research. Here, we describe the discovery and development of aliskiren, an orally active renin inhibitor, which became the first drug in its class to receive regulatory approval. In 2007, it was approved for the treatment of hypertension by the US Food and Drug Administration and the European Medicines Agency.
- View At a Glance
Author affiliations
- Speedel, Hirschgässlein 11, Basel CH 4051, Switzerland.
Correspondence to: Chris Jensen1 Email: chris.jensen@speedel.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Using Plasma Renin (PRA) Testing to Design Follow-Up Drug Treatment Strategies in Hypertensive Patients Already Taking Antirenin System DrugsAmerican Journal of Hypertension News and Views
RESEARCH
Aliskiren Monotherapy Results in the Greatest and the Least Blood Pressure Lowering in Patients With High- and Low-Baseline PRA Levels, RespectivelyAmerican Journal of Hypertension Original Article
Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor AliskirenClinical Pharmacology & Therapeutics Article Response
Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertensionHypertension Research Original Article
See all 19 matches for Research
